- Home
- PZC vs IPHA Comparison
PZC vs IPHA Comparison
Compare PZC & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZC
- IPHA
- Stock Information
- Founded
- PZC 2002
- IPHA 1999
- Country
- PZC United States
- IPHA France
- Employees
- PZC N/A
- IPHA N/A
- Industry
- PZC Investment Managers
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- PZC Finance
- IPHA Health Care
- Exchange
- PZC Nasdaq
- IPHA Nasdaq
- Market Cap
- PZC 150.3M
- IPHA 148.3M
- IPO Year
- PZC N/A
- IPHA 2019
- Fundamental
- Price
- PZC $6.69
- IPHA $1.69
- Analyst Decision
- PZC
- IPHA Strong Buy
- Analyst Count
- PZC 0
- IPHA 1
- Target Price
- PZC N/A
- IPHA $11.50
- AVG Volume (30 Days)
- PZC 48.2K
- IPHA 49.9K
- Earning Date
- PZC 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- PZC 4.68%
- IPHA N/A
- EPS Growth
- PZC N/A
- IPHA N/A
- EPS
- PZC N/A
- IPHA N/A
- Revenue
- PZC N/A
- IPHA $36,202,722.00
- Revenue This Year
- PZC N/A
- IPHA N/A
- Revenue Next Year
- PZC N/A
- IPHA $101.65
- P/E Ratio
- PZC N/A
- IPHA N/A
- Revenue Growth
- PZC N/A
- IPHA N/A
- 52 Week Low
- PZC $6.30
- IPHA $1.29
- 52 Week High
- PZC $8.20
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- PZC 36.43
- IPHA 42.95
- Support Level
- PZC $6.62
- IPHA $1.60
- Resistance Level
- PZC $6.74
- IPHA $1.87
- Average True Range (ATR)
- PZC 0.09
- IPHA 0.13
- MACD
- PZC -0.01
- IPHA -0.04
- Stochastic Oscillator
- PZC 21.95
- IPHA 16.67
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.